CytomX Therapeutics, Inc. (CTMX)

NASDAQ: CTMX · Real-Time Price · USD
1.010
-0.040 (-3.81%)
Nov 4, 2024, 4:00 PM EST - Market closed
-3.81%
Market Cap 78.90M
Revenue (ttm) 119.57M
Net Income (ttm) 11.09M
Shares Out 78.12M
EPS (ttm) 0.13
PE Ratio 7.39
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,064,686
Open 1.050
Previous Close 1.050
Day's Range 0.990 - 1.070
52-Week Range 0.988 - 5.850
Beta 1.06
Analysts Buy
Price Target 5.77 (+471.29%)
Earnings Date Nov 7, 2024

About CTMX

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 122
Stock Exchange NASDAQ
Ticker Symbol CTMX
Full Company Profile

Financial Performance

In 2023, CytomX Therapeutics's revenue was $101.21 million, an increase of 90.38% compared to the previous year's $53.16 million. Losses were -$569,000, -99.43% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $5.77, which is an increase of 471.29% from the latest price.

Price Target
$5.77
(471.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announce...

2 months ago - GlobeNewsWire

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -

3 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced...

4 months ago - GlobeNewsWire

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promoti...

5 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced ...

5 months ago - GlobeNewsWire

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May ...

6 months ago - GlobeNewsWire

CytomX stock down 30% despite encouraging cancer study results

CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.

6 months ago - Invezz

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

6 months ago - GlobeNewsWire

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -

6 months ago - GlobeNewsWire

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -

6 months ago - GlobeNewsWire

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -

6 months ago - GlobeNewsWire

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-90...

6 months ago - Seeking Alpha

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the fir...

7 months ago - GlobeNewsWire

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -

7 months ago - GlobeNewsWire

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the app...

8 months ago - GlobeNewsWire

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -

8 months ago - GlobeNewsWire

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chie...

8 months ago - Seeking Alpha

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -

8 months ago - GlobeNewsWire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it...

8 months ago - GlobeNewsWire

CytomX Therapeutics to Present at Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that man...

8 months ago - GlobeNewsWire

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

10 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

10 months ago - GlobeNewsWire

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in  the 2 nd half of 2024 -

10 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

11 months ago - GlobeNewsWire

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - C...

1 year ago - Seeking Alpha